Astrocyte-targeted therapies represent an emerging frontier in Parkinson's disease (PD) treatment. These approaches aim to modulate astrocyte function to provide neuroprotection, support metabolic coupling between astrocytes and neurons, and promote glial fibrillary acidic protein (GFAP)-mediated pathways. This page tracks companies developing these innovative therapeutic modalities.
Astrocyte modulation therapies aim to restore or enhance normal astrocyte functions that become dysfunctional in Parkinson's disease. Key approaches include:
Direct astrocyte reprogramming aims to convert astrocytes into supportive neuronal subtypes or restore youthful astrocyte states:
Focus: Glial modulation and neuroprotection
Neuraly is developing therapies targeting glial cells in neurodegenerative diseases. Their approach focuses on modulating astrocyte function to provide neuroprotection in Parkinson's disease.
Focus: Gene therapy for astrocyte targeting
Prevail Therapeutics (acquired by Eli Lilly) developed gene therapy approaches targeting astrocytes for Parkinson's disease. Their work includes delivery of therapeutic genes to astrocytes using AAV vectors.
Focus: AAV gene therapy delivery to astrocytes
Passage Bio develops AAV-delivered gene therapies targeting various neurological disorders, including approaches to deliver therapeutic genes to astrocytes in PD.
Glial fibrillary acidic protein (GFAP) is a key marker for astrocyte activation. In Parkinson's disease:
Astrocytes provide critical metabolic support to neurons:
Therapies enhancing these functions may protect dopaminergic neurons.
| Company | Approach | Stage | Notes |
|---|---|---|---|
| Various academic programs | Astrocyte reprogramming | Preclinical | Early research phase |
| Gene therapy companies | AAV-astrocyte targeting | Preclinical/Phase 1 | Delivery challenges |